Search our Innovation Portfolio
Summary
Tika is developing innovative reagents for improving rapid diagnosis of mycobacterial infections. Tika has discovered and optimised the use of a new supplement that in a laboratory setting can significantly reduce the time for detection in liquid media. In addition, the Company has shown that this supplement can increase the sensitivity and speed of growing colonies on solid media which could significantly improve the speed and accuracy of antibiotic resistance testing. An assessment tool for managing the treatment of depression P1vital has developed a machine learning based online app, the PReDicT Test, designed for patients with depression to predict early in treatment whether their antidepressant is working. Identifying an effective antidepressant within days not months provides benefit to millions of patients and reduces the economic burden of depression which costs the NHS and the wider economy over \xa311bn/yr.
Funding
Review available funding amount, funding date, investors, and linked company information related to Search our Innovation Portfolio in the interactive ISVWorld profile.